Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers

A few individuals can control HIV infection without the need for antiretroviral treatment and are referred to as HIV controllers. We have studied HIV controllers who suddenly lose this ability and present with high in vivo viral replication and decays in their CD4+ T-cell counts to identify potential immune and virological factors that were responsible for initial virus control. We identify in vitro-determined reductions in the ability of CD8 T cells to suppress viral control and the presence of PD-1-expressing CD8+ T cells with a naive immune phenotype as potential predictors of in vivo loss of virus control. The findings could be important for the clinical management of HIV controller individuals, and it may offer an important tool to anticipate viral rebound in individuals in clinical studies that include combination antiretroviral therapy (cART) treatment interruptions and which, if not treated quickly, could pose a significant risk to the trial participants. ABSTRACT Elite and viremic HIV controllers are able to control their HIV infection and maintain undetectable or low-level viremia in the absence of antiretroviral treatment. Despite extensive studies, the immune factors responsible for such exclusive control remain poorly defined. We identified a cohort of 14 HIV controllers that suffered an abrupt loss of HIV control (LoC) to investigate possible mechanisms and virological and immunological events related to the sudden loss of control. The in-depth analysis of these subjects involved the study of cell tropism of circulating virus, evidence for HIV superinfection, cellular immune responses to HIV, as well as an examination of viral adaptation to host immunity by Gag sequencing. Our data demonstrate that a poor capacity of T cells to mediate in vitro viral suppression, even in the context of protective HLA alleles, predicts a loss of viral control. In addition, the data suggest that inefficient viral control may be explained by an increase of CD8 T-cell activation and exhaustion before LoC. Furthermore, we detected a switch from C5- to X4-tropic viruses in 4 individuals after loss of control, suggesting that tropism shift might also contribute to disease progression in HIV controllers. The significantly reduced inhibition of in vitro viral replication and increased expression of activation and exhaustion markers preceding the abrupt loss of viral control may help identify untreated HIV controllers that are at risk of losing control and may offer a useful tool for monitoring individuals during treatment interruption phases in therapeutic vaccine trials. IMPORTANCE A few individuals can control HIV infection without the need for antiretroviral treatment and are referred to as HIV controllers. We have studied HIV controllers who suddenly lose this ability and present with high in vivo viral replication and decays in their CD4+ T-cell counts to identify potential immune and virological factors that were responsible for initial virus control. We identify in vitro-determined reductions in the ability of CD8 T cells to suppress viral control and the presence of PD-1-expressing CD8+ T cells with a naive immune phenotype as potential predictors of in vivo loss of virus control. The findings could be important for the clinical management of HIV controller individuals, and it may offer an important tool to anticipate viral rebound in individuals in clinical studies that include combination antiretroviral therapy (cART) treatment interruptions and which, if not treated quickly, could pose a significant risk to the trial participants.

[1]  M. Lederman,et al.  HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers , 2018, The Journal of clinical investigation.

[2]  B. Walker,et al.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.

[3]  B. Clotet,et al.  Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses , 2018, Journal of Virology.

[4]  M. C. Ortiz,et al.  Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers , 2018, BMC Medicine.

[5]  Todd M. Allen,et al.  Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient , 2018, Retrovirology.

[6]  J. Prado,et al.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection , 2017, Journal of Virology.

[7]  M. Lederman,et al.  Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals , 2017, AIDS Research and Therapy.

[8]  M. Carrington,et al.  Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller , 2017, EBioMedicine.

[9]  R. Paredes,et al.  Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death , 2014, PloS one.

[10]  B. Walker,et al.  CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles , 2016, Journal of Virology.

[11]  Felipe García,et al.  Rate and predictors of progression in elite and viremic HIV-1 controllers , 2016, AIDS.

[12]  Marion C Lanteri,et al.  Human memory T cells with a naïve phenotype accumulate with aging and respond to persistent viruses , 2016, Nature Immunology.

[13]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[14]  Kathleen V Fitch,et al.  Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV , 2015, AIDS.

[15]  A. Westfall,et al.  Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts , 2015, AIDS.

[16]  M. Johnson,et al.  Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study , 2015, PloS one.

[17]  P. Uhlén,et al.  Infection by Toxoplasma gondii Induces Amoeboid-Like Migration of Dendritic Cells in a Three-Dimensional Collagen Matrix , 2015, PloS one.

[18]  L. Meyer,et al.  Immunologic and Virologic Progression in HIV Controllers: The Role of Viral “Blips” and Immune Activation in the ANRS CO21 CODEX Study , 2015, PloS one.

[19]  M. Biffoni,et al.  Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection , 2015, Journal of Virology.

[20]  S. Le Gall,et al.  Variable Processing and Cross-presentation of HIV by Dendritic Cells and Macrophages Shapes CTL Immunodominance and Immune Escape , 2015, PLoS pathogens.

[21]  D. Follmann,et al.  CD8+ T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types , 2014, EBioMedicine.

[22]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[23]  Angela R. McLean,et al.  Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence , 2014, Proceedings of the National Academy of Sciences.

[24]  H. Schuitemaker,et al.  Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. , 2014, The lancet. HIV.

[25]  À. Olvera,et al.  HLA-B*35-PX and HLA-B*35-PY subtype differentiation does not predict observed differences in level of HIV control in a Peruvian MSM cohort. , 2014, AIDS.

[26]  J. Blankson,et al.  Comparative Analysis of the Capacity of Elite Suppressor CD4+ and CD8+ T Cells To Inhibit HIV-1 Replication in Monocyte-Derived Macrophages , 2014, Journal of Virology.

[27]  R. Paredes,et al.  Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. , 2013, The Journal of antimicrobial chemotherapy.

[28]  B. Angus,et al.  Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. , 2013, Journal of immunological methods.

[29]  R. Swanstrom,et al.  HIV-1 pathogenesis: the virus. , 2012, Cold Spring Harbor perspectives in medicine.

[30]  B. Burwitz,et al.  CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller , 2012, Retrovirology.

[31]  B. Walker,et al.  HIV and HLA class I: an evolving relationship. , 2012, Immunity.

[32]  A. McMichael,et al.  Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. , 2012, The Journal of infectious diseases.

[33]  D. Heckerman,et al.  CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control , 2012, PloS one.

[34]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[35]  D. Kaufmann,et al.  HIV controllers: a multifactorial phenotype of spontaneous viral suppression. , 2011, Clinical immunology.

[36]  J. Prado,et al.  Immune correlates of HIV control. , 2011, Current medicinal chemistry.

[37]  S. Elahi,et al.  Protective HIV-specific CD8+ T cells evade Treg cell suppression , 2011, Nature Medicine.

[38]  F. Pereyra,et al.  High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control , 2011, Journal of Virology.

[39]  J. Mellors,et al.  HIV-1 Continues To Replicate and Evolve in Patients with Natural Control of HIV Infection , 2010, Journal of Virology.

[40]  A. Telenti,et al.  HIV-1 elite controllers: beware of super-infections. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[41]  B. Agan,et al.  Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. , 2009, The Journal of infectious diseases.

[42]  Elizabeth T. Cirulli,et al.  Common Genetic Variation and the Control of HIV-1 in Humans , 2009, PLoS genetics.

[43]  Christian Brander,et al.  Virological, Immune and Host genetics Markers in the Control of HIV Infection , 2009, Disease markers.

[44]  David W. Haas,et al.  HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins , 2009, PloS one.

[45]  C. Rouzioux,et al.  Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.

[46]  H. Schuitemaker,et al.  Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  Todd M. Allen,et al.  Immune-driven recombination and loss of control after HIV superinfection , 2008, The Journal of experimental medicine.

[48]  Steven G. Deeks,et al.  HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.

[49]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[50]  Jeffrey N. Martin,et al.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.

[51]  B. Walker,et al.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. , 2007, Immunity.

[52]  Jacques Fellay,et al.  A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.

[53]  H. Schuitemaker,et al.  Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease , 2007, Journal of Virology.

[54]  P. Kaleebu,et al.  Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort , 2007, Journal of acquired immune deficiency syndromes.

[55]  Asier Sáez-Cirión,et al.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.

[56]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[57]  Bette T. Korber,et al.  Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.

[58]  S. Lewin,et al.  Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts , 2005, Journal of acquired immune deficiency syndromes.

[59]  Eric J. Arts,et al.  Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression , 2005, Journal of Virology.

[60]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[61]  D. Richman,et al.  Incidence of HIV superinfection following primary infection. , 2004, JAMA.

[62]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[63]  S. Migueles,et al.  The Functional Profile of Primary Human Antiviral CD8+ T Cell Effector Activity Is Dictated by Cognate Peptide Concentration , 2004, The Journal of Immunology.

[64]  F. M. Marincola,et al.  Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities , 2004, Journal of Virology.

[65]  Stephen J O'Brien,et al.  The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.

[66]  Todd M. Allen,et al.  HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus , 2002, Nature.

[67]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[68]  B. Walker,et al.  The great escape – AIDS viruses and immune control , 1999, Nature Medicine.

[69]  S. Buchbinder,et al.  Long‐term HIV‐1 infection without immunologic progression , 1994, AIDS.

[70]  M. Nei,et al.  Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.

[71]  D. Ho,et al.  Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.

[72]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[73]  J. Felsenstein CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP , 1985, Evolution; international journal of organic evolution.